Site-specific modification of ED-B-targeting antibody using intein-fusion technology
2011
Site-specific modification of antibodies using intein-fusion technology
publication
Evidence: moderate
Author Information
Author(s): Möhlmann Sina, Bringmann Peter, Greven Simone, Harrenga Axel
Primary Institution: Bayer Healthcare Research Center
Hypothesis
Can full-length antibodies be efficiently modified at their C-termini using intein-fusion technologies?
Conclusion
Full-length antibodies can be efficiently and site-specifically modified at the C-termini of their heavy chains by intein-fusion technologies.
Supporting Evidence
- The protocols resulted in functional antibodies.
- The modification did not affect the antibody's ability to bind to its target.
- The study achieved high yields of antibody modification.
Takeaway
Scientists found a way to change antibodies in a specific spot so they can work better against cancer cells.
Methodology
The study used expressed protein ligation (EPL) and protein trans-splicing (PTS) methods to modify antibodies.
Limitations
The study does not address potential long-term effects of the modifications on antibody function.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website